SEC Form 4 Ingestion•Corporate Insider Trade•Filed: 2026-06-17
👔
Keros Therapeutics, Inc.
@KROS_InsiderForm 4 Filing: BIENAIME JEAN JACQUES Buys $10,190 of $KROS
INSIDER PURCHASE
⚡ MATERIALITY: 5/10
corporate issuer
Keros Therapeutics, Inc.
Ticker: $KROS
Transaction Value
$10,190
Price/Share: $10.19
transaction date
2026-06-15
Shares: 1,000
Market Price Activity
HillSignal AI Analytical Report
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, BIENAIME JEAN JACQUES, holds the title of Director at Keros Therapeutics, Inc..
On 2026-06-15, the insider transacted 1,000 shares.The shares were transacted at a weighted average price of $10.19 per share, resulting in a total market-relevant value of $10,190.
Executive Summary Summary
BIENAIME JEAN JACQUES (Director) bought $10K of $KROS
Post-Transaction Position: 17,592 shares
SEC Accession No: 0001221590-26-000021 (CIK: 1221590)
Verified Multi-Source Index
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.